New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
08:13 EDTCRMECardiome reaches agreement with Merck to reitre debt and close line of credit
Cardiome Pharma announced that the company has reached an agreement with Merck to settle its debt obligations stemming from the companies' collaboration and license agreement for vernakalant, signed in April 2009. Under the terms of the settlement agreement, Cardiome will pay Merck $20M on or before March 31, 2013, to settle its outstanding debt of $50M owed to Merck. The payment will be made from Cardiome's existing cash balance, which totalled $53.6M at the end of September. Pursuant to the vernakalant collaboration and license agreement Merck had granted Cardiome an interest-bearing credit facility of up to $100M secured by a first priority security interest in the company's vernakalant patents throughout the world and all associated proceeds. The settlement between Cardiome and Merck will terminate the credit facility and, upon payment of the $20M settlement amount, will release and discharge the collateral security taken in respect of the advances under the line of credit.
News For CRME From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:24 EDTCRMECardiome enters development, commercialization agreement with Eddingpharm
Cardiome Pharma announced that one of its subsidiaries has entered into an agreement with Eddingpharm to develop and commercialize BRINAVESS in China, Taiwan, and Macau and re-launch BRINAVESS in Hong Kong. Eddingpharm will be responsible for any clinical trials and regulatory approvals required to commercialize BRINAVESS in the countries covered by the agreement. Under the terms of the agreement, Eddingpharm has agreed to an upfront payment of $1.0M and specific annual commercial goals for BRINAVESS. Cardiome is also eligible to receive regulatory milestone payments of up to $3.0M. Other financial details have not been disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use